MiR-302a sensitizes leukemia cells to etoposide by targeting Rad52

Xiaoning Liu; Chun Heng; Yuanyuan Li; Liang Yu

doi:10.18632/oncotarget.17878

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MiR-302a sensitizes leukemia cells to etoposide by targeting Rad52

Xiaoning Liu, Chun Heng, Yuanyuan Li and Liang Yu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:73884-73891. https://doi.org/10.18632/oncotarget.17878

Metrics: PDF 2048 views | HTML 2517 views | ?

Abstract

Xiaoning Liu1, Chun Heng1, Yuanyuan Li1 and Liang Yu2

1Central Laboratory, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu Province, 223300, China

2Hematology Department, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu Province, 223300, China

Correspondence to:

Liang Yu, email: [email protected]

Keywords: miR-302a, acute myeloid leukemia (AML), VP-16 resistance, Rad52

Received: August 08, 2016 Accepted: March 29, 2017 Published: May 16, 2017

ABSTRACT

miR-302a have been reported to participate in various physiological and pathological processes, however, a role for miR-302a in etoposide (VP-16) resistance of acute myeloid leukemia (AML) has not been reported. In this study, the aberrant expression of miR-302a was analyzed in patients with AML and in the AML HL-60 and U937 cell lines. Overexpression of miR-302a, by targeting the 3′UTR of Rad52, enhanced VP-16 sensitivity in the HL-60 and U937 cell. Accordingly, knockdown of Rad52 sensitized the HL-60 and U937 cells to VP-16-induced apoptosis and proliferation suppression. In addition, miR-302a enhanced the tumor-suppressive effect of VP-16 in a xenograft model of human HL-60 and U937 cell lines. Moreover, miR-302a repressed the AKT/Gsk3β/β-catenin pathway after Rad52 inhibition. Reintroduction of Rad52 reversed miR-302a-induced signaling suppression. The results of the present study demonstrated that miR-302a may be a target for the treatment of AML and a potential indicator of the therapeutic sensitivity of AML to VP-16.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17878

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

MiR-302a sensitizes leukemia cells to etoposide by targeting Rad52

Abstract